Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $40.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its price target boosted by Scotiabank from $35.00 to $40.00 in a research note published on Thursday,Benzinga reports. The firm currently has a sector outperform rating on the stock.

Several other brokerages have also recently weighed in on TEVA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, January 21st. JPMorgan Chase & Co. lifted their target price on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Piper Sandler upped their price target on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, December 22nd. Bank of America raised their price objective on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Finally, Jefferies Financial Group upped their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $36.00.

Teva Pharmaceutical Industries Trading Up 3.1%

Teva Pharmaceutical Industries stock opened at $34.08 on Thursday. Teva Pharmaceutical Industries has a 52-week low of $12.47 and a 52-week high of $34.11. The company has a market cap of $39.09 billion, a P/E ratio of 28.40, a P/E/G ratio of 1.88 and a beta of 0.66. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. The business has a 50-day simple moving average of $30.49 and a two-hundred day simple moving average of $23.20.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.31. The firm had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 48.20%. The business’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Analysts predict that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 12,300 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total transaction of $371,460.00. Following the completion of the transaction, the chief accounting officer directly owned 5,650 shares of the company’s stock, valued at $170,630. The trade was a 68.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Richard Daniell sold 115,468 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the completion of the sale, the vice president directly owned 48,384 shares of the company’s stock, valued at approximately $1,387,653.12. The trade was a 70.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 622,060 shares of company stock worth $17,076,965. 0.49% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Grove Bank & Trust boosted its holdings in Teva Pharmaceutical Industries by 300.0% during the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after acquiring an additional 750 shares during the period. Advisors Asset Management Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth $41,000. Cromwell Holdings LLC boosted its stake in shares of Teva Pharmaceutical Industries by 40.3% during the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after purchasing an additional 629 shares during the period. Sound Income Strategies LLC grew its holdings in shares of Teva Pharmaceutical Industries by 3,715.8% in the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock worth $49,000 after purchasing an additional 2,824 shares during the last quarter. Finally, MAI Capital Management grew its holdings in shares of Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after purchasing an additional 697 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 fundamentals beat expectations — Teva reported stronger-than-expected results (reported EPS and revenue outperformed consensus), revenue grew year-over-year driven by a Sanofi milestone and Austedo growth, and management set FY‑2026 EPS guidance of roughly 2.57–2.77, supporting a higher valuation. TEVA’s Q4 Earnings Beat, Branded Drugs Drive Revenue Growth
• Positive Sentiment: Barclays raised its price target to $38 and set an “overweight” rating, signaling upside from current levels and lending third‑party validation to the stock’s outlook. Barclays raises TEVA price target to $38
• Positive Sentiment: Truist increased its price target to $38 with a “buy” rating, reinforcing bullish analyst sentiment following the quarter. Truist raises TEVA price target to $38
• Positive Sentiment: Scotiabank lifted its target to $40 and moved to “sector outperform,” the highest target among recent broker notes, which may attract more investor interest. Scotiabank raises TEVA price target to $40

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.